This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Biosimilars overview

What is a biosimilar

The future of biosimilars

Considerations for biologic switching

A biosimilar is a biologic product that is approved based on a demonstration that shows that it is highly similar to an approved biologic product, known as the reference product.1-3

Biosimilars are developed to be highly similar to the reference product with no clinically meaningful differences in terms of quality, efficacy and safety.1-3

Biosimilars can support a more sustainable healthcare system,4-7 expanding treatment options and enabling cost savings8 without compromising safety or efficacy.1-3,9

Potential Benefits of Biosimilars

Potential benefits of biosimilars for patients, payers and providers include:4-6​​​​​​​

‘’Biosimilars have the potential to offer the NHS considerable cost savings especially as biological medicines are often expensive and are often used to treat long-term conditions.10’’

– NICE


Explore more

Rheumatoid arthritis safety

Learn about the safety profile of Inflectra in patients with rheumatoid arthritis

Learn more

Rheumatoid arthritis dosing

Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis

Find out more

References
  1. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: FDA; 2015.
  2. McCamish M, Woollett G. Worldwide Experience with Biosimilar Development. MAbs. 2011. 3(2):209-217.
  3. Kay J, Feagen BG, Guirguis MS, et al. Health Canada/BIOTECanada Summit on Regulatory and Clinical Topics Related to Subsequent Entry Biologics (biosimilars). Biologicals. 2012. 40(6):517-527.
  4. Scheinberg MA, Kay J. The Advent of Biosimilar Therapies in Rheumatology—“O Brave New World.” Nat Rev Rheumatol. 2012. 8(7):430-436.
  5. Henry D, Taylor C. Pharmacoeconomics of Cancer Therapies: Considerations with the Introduction of Biosimilars. Semin Oncol. 2014. 41(suppl 3):S13-S20.
  6. Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and Biosimilars in Psoriasis: What the Dermatologist Needs to Know. J Am Acad Dermatol. 2012. 66(2):317-322.
  7. Blackstone EA, Fuhr Jr JP. Biologics & Biosimilars: The Possibility of Encouraging Innovation And Competition. The SciTech Lawyer. [online]. 2015 [Accessed March 2021]. 11(3). Available from: https://www.americanbar.org/content/dam/aba/publications/scitech_lawyer/2015/spring/biologics_biosimilars_possibility_encouraging_innovation_competition.authcheckdam.pdf
  8. Haustein R, et al. GaBi Journal. 2012. 1(3-4):120-126.
  9. The Biosimilars Forum. Biosimilars Overview. [online]. 2017 [Accessed March 2021]. Available from: http://www.biosimilarsforum.org/sites/default/files/uploads/Image-Resources/biosimilars_overview_02_28_17_v1.pdf.
  10. NICE. Biosimilar Medicines. [online]. 2016 [Accessed March 2021]. Available from: https://www.nice.org.uk/advice/ktt15/resources/biosimilar-medicines-pdf-58757954414533.
PP-IFA-GBR-0404. March 2021

Quick Links

  • Inflammatory bowel disease

  • Infliximab mechanism of action

  • Support & Resources

Learn about the evidence supporting the use of Inflectra in patients with Crohn’s disease.

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No